MCID: PDT015
MIFTS: 35

Pediatric Supratentorial Ependymoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Pediatric Supratentorial Ependymoma

MalaCards integrated aliases for Pediatric Supratentorial Ependymoma:

Name: Pediatric Supratentorial Ependymoma 12 15
Childhood Supratentorial Ependymoma 12 17 74
Pediatric Supratentorial Ependymoblastoma 12
Pediatric Cerebral Ependymoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7502
NCIt 51 C9043
UMLS 74 C0278650

Summaries for Pediatric Supratentorial Ependymoma

MalaCards based summary : Pediatric Supratentorial Ependymoma, also known as childhood supratentorial ependymoma, is related to ependymoma and benign ependymoma, and has symptoms including seizures, vomiting and headache. An important gene associated with Pediatric Supratentorial Ependymoma is RELA (RELA Proto-Oncogene, NF-KB Subunit), and among its related pathways/superpathways are T cell receptor signaling pathway and NF-kappaB Signaling. The drugs Carboplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and spinal cord, and related phenotype is Upregulation of RLR pathway after Sendai virus (SeV) infection.

Related Diseases for Pediatric Supratentorial Ependymoma

Diseases related to Pediatric Supratentorial Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 ependymoma 29.9 C11orf95 RELA
2 benign ependymoma 10.2
3 reticuloendotheliosis 9.4 REL RELA

Symptoms & Phenotypes for Pediatric Supratentorial Ependymoma

UMLS symptoms related to Pediatric Supratentorial Ependymoma:


seizures, vomiting, headache, nausea

GenomeRNAi Phenotypes related to Pediatric Supratentorial Ependymoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Upregulation of RLR pathway after Sendai virus (SeV) infection GR00302-A 8.62 REL RELA

Drugs & Therapeutics for Pediatric Supratentorial Ependymoma

Drugs for Pediatric Supratentorial Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
2
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
4
leucovorin Approved Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
6
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
7
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
8
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
9
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
10
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
11
Ondansetron Approved Phase 3 99614-02-5 4595
12
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
13
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
16
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
17 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
18 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Antimetabolites, Antineoplastic Phase 3,Phase 2,Not Applicable
21 Vitamin B9 Phase 3,Phase 2,Not Applicable
22 Folate Phase 3,Phase 2,Not Applicable
23 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
24 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
26 Antimetabolites Phase 3,Phase 2,Not Applicable
27 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
29 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
31 Vitamin B Complex Phase 3,Phase 2,Not Applicable
32 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
34 Keratolytic Agents Phase 3,Phase 2
35 Podophyllotoxin Phase 3,Phase 2 518-28-5
36 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Antiemetics Phase 3,Phase 1
38 Emetics Phase 3
39 BB 1101 Phase 3,Phase 2,Phase 1
40 Peripheral Nervous System Agents Phase 3,Phase 1
41 Autonomic Agents Phase 3,Phase 1
42
Mesna Approved, Investigational Phase 2,Phase 1 3375-50-6 598
43
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
44
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
45
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
46
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807
47
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
48
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
49
Carmustine Approved, Investigational Phase 2 154-93-8 2578
50
Sodium Citrate Approved, Investigational Phase 2 68-04-2

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
4 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
5 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
6 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
7 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
8 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
9 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
10 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
11 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
12 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
13 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
14 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
15 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
16 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
17 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
19 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
20 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
21 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
22 TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma Terminated NCT00074334 Phase 1, Phase 2
23 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
24 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
25 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
26 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
27 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
28 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
29 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
30 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
31 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
32 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
33 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
34 Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas Completed NCT00002753 Phase 1
35 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
36 DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
37 ABT-751 in Treating Young Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
38 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
39 Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
40 Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
41 Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
42 Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Completed NCT00107458 Phase 1 valproic acid
43 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
44 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
45 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
46 MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer Terminated NCT00572182 Phase 1 MK-0752
47 Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate
48 Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors Terminated NCT00112619 Phase 1 topotecan hydrochloride
49 Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment Withdrawn NCT00458744 Phase 1 talotrexin
50 Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial Completed NCT01407744

Search NIH Clinical Center for Pediatric Supratentorial Ependymoma

Genetic Tests for Pediatric Supratentorial Ependymoma

Anatomical Context for Pediatric Supratentorial Ependymoma

MalaCards organs/tissues related to Pediatric Supratentorial Ependymoma:

42
Brain, Bone, Spinal Cord, Bone Marrow, T Cells

Publications for Pediatric Supratentorial Ependymoma

Articles related to Pediatric Supratentorial Ependymoma:

# Title Authors Year
1
Pediatric Supratentorial Ependymoma: Surgical, Clinical, and Molecular Analysis. ( 29917116 )
2018
2
MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma. ( 30027327 )
2018

Variations for Pediatric Supratentorial Ependymoma

Expression for Pediatric Supratentorial Ependymoma

Search GEO for disease gene expression data for Pediatric Supratentorial Ependymoma.

Pathways for Pediatric Supratentorial Ependymoma

Pathways related to Pediatric Supratentorial Ependymoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.22 REL RELA
2 12.2 REL RELA
3
Show member pathways
12.17 REL RELA
4
Show member pathways
12.13 REL RELA
5
Show member pathways
12.06 REL RELA
6
Show member pathways
12.06 REL RELA
7
Show member pathways
12.04 REL RELA
8
Show member pathways
12 REL RELA
9
Show member pathways
11.99 REL RELA
10
Show member pathways
11.99 REL RELA
11
Show member pathways
11.96 REL RELA
12 11.95 REL RELA
13
Show member pathways
11.93 REL RELA
14 11.91 REL RELA
15
Show member pathways
11.88 REL RELA
16
Show member pathways
11.87 REL RELA
17
Show member pathways
11.86 REL RELA
18
Show member pathways
11.83 REL RELA
19
Show member pathways
11.82 REL RELA
20
Show member pathways
11.76 REL RELA
21 11.71 REL RELA
22
Show member pathways
11.67 REL RELA
23
Show member pathways
11.61 REL RELA
24
Show member pathways
11.61 REL RELA
25 11.53 REL RELA
26
Show member pathways
11.5 REL RELA
27
Show member pathways
11.37 REL RELA
28 11.35 REL RELA
29 11.35 REL RELA
30
Show member pathways
11.28 REL RELA
31
Show member pathways
11.26 REL RELA
32 11.21 REL RELA
33 11.2 REL RELA
34
Show member pathways
11.17 REL RELA
35 11.14 REL RELA
36
Show member pathways
11.07 REL RELA
37 10.97 REL RELA
38 10.9 REL RELA
39
Show member pathways
10.85 REL RELA
40 10.77 REL RELA
41 10.47 REL RELA
42 9.77 REL RELA

GO Terms for Pediatric Supratentorial Ependymoma

Cellular components related to Pediatric Supratentorial Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 8.62 REL RELA

Biological processes related to Pediatric Supratentorial Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.26 REL RELA
2 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.16 REL RELA
3 response to cytokine GO:0034097 8.96 REL RELA
4 NIK/NF-kappaB signaling GO:0038061 8.62 REL RELA

Molecular functions related to Pediatric Supratentorial Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 8.96 REL RELA
2 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 8.62 REL RELA

Sources for Pediatric Supratentorial Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....